513, 887

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000824 A1

(51) International Patent Classification[7]: C07D 295/15

(21) International Application Number: PCT/EP2003/050241

(22) International Filing Date: 19 June 2003 (19.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02077749.6 24 June 2002 (24.06.2002) EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA N.V.** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GUILLAUME, Michel, Joseph, Maurice, André** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **CUYPERS, Jozef, Ludo, Jan** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **VERVEST, Ivan, Joseph, Maria** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **LEURS, Stefan, Marcel, Herman** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **DE SMAELE, Dirk** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*
— *of inventorship (Rule 4.17(iv)) for US only*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PRODUCTION OF *N*-(2,6-DIMETHYL-PHENYL)-2-PIPERAZIN-1-YL-ACETAMIDE

(57) Abstract: The present invention relates to a novel process, suitable for industrial exploitation for the production of *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide, also known as *N*-lidocaine, obtained from the reaction of piperazine with *N*-haloacteyl-2,6-xylidine. The process comprises the consecutive steps a) through f): a) reacting piperazine with *N*-haloacetyl-2,6-xylidine in a molar ratio between about 1/1 and about 6/1 in an aqueous solvent in which has been dissolved an equimolar amount of HCl; b) separating the solid formed in step a) from the reaction mixture; c) neutralizing the filtrate; d) extracting the filtrate with a solvent which is not or only to a small extent miscible with the aqueous solvent mentioned in step a); e) crystallizing the *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide from the solvent mentioned in step (d) and f) separating the solid obtained in step e) from the solvent mentioned in step d).

WO 2004/000824 A1

PROCESS FOR THE PRODUCTION OF *N*-(2,6-DIMETHYL-PHENYL)-2-PIPERAZIN-1-YL -ACETAMIDE.

The present invention relates to a process for the production of *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide, a lidocaine derivative, obtained from the reaction of piperazine with *N*-haloacetyl-2,6-xylidine.

Such production process is known from WO 96/40664 (Dade Chemistry Systems Inc.) in which piperazine (Formula I) is reacted with *N*-chloroacetyl-2,6-xylidine (Formula II) to produce an oily residue that solidifies on cooling. Said process can be depicted by the reaction scheme below.



I II III

Due to the specific choice of reagents, invariably an adduct (Formula IV) is formed.



IV

Several processes have been developed in order to reduce the amount of adduct, among which a process by which an excess of piperazine is used (WO 96/40664) and a process in which the piperazine is mono-protected (EP 126 449 B1 - Syntex Inc.), EP 582 164 B1- Bristol-Myers Squibb Company).

However, all of the known methods have the disadvantage that they are not well suitable for the exploitation of the reaction on an industrial scale, in particular for a process that produces a dispersion or slurry from which the solid part can be obtained by industrial separation methods, in particular by filtration.

According to the method disclosed in WO 96/40664, the solvent in which the reaction product (Formula III) is formed needs to be removed entirely, thereby producing an oily residue, which solidifies after cooling. The entire removal of the solvent requires large amounts of energy and the formation of said solid as an oily residue is undesirable in industrial scale reactors since it is formed on the inner surfaces of the reactor, in particular on the walls and rotor blades, and therefore it is virtually impossible to remove and collect. The method disclosed in WO 96/40664 has the further disadvantage that a large excess of piperazine is used (ratio of 10/1).

Using protected piperazine is commercially undesirable because of the extra process steps needed to protect and deprotect the nitrogen.

N-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide may be used as a pharmaceutical intermediate in the preparation process of 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives, which are usefull as substance-P antagonists (EP 862 566 B1, Janssen Pharmaceutica NV).

The object of the present invention is to provide a process for the production of *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide obtained from the reaction of piperazine with *N*-haloacetyl-2,6-xylidine which is suitable for industrial scale reactors, in particular to provide a process in which the undesired adduct according to Formula (IV) or the desired end product according to Formula (III) or both are separated from the reaction mixture by filtration.

The further object of the present invention is to provide a process for the production of *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide obtained from the reaction of piperazine with *N*-haloacetyl-2,6-xylidine with a purity > 95 %.

Very surprisingly, the inventors have found that the drawbacks of the known processes can be overcome by a process which comprises the subsequent steps a) through f) :

a) reacting piperazine with *N*-haloacetyl-2,6-xylidine in a molar ratio between about 1/1 and about 6/1 in an aqueous solvent in which has been dissolved an about equimolar amount of HCl, relative to the molar amount of piperazine ;

b) separating the solid formed in step a) from the reaction mixture ;

c) neutralizing the filtrate ;

d) extracting the filtrate with a solvent which is not or only to a small extent miscible with the aqueous solvent mentioned in step a) ;
e) crystallizing the *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide from the solvent mentioned in step d) and
f) separating the solid obtained in step e) from the solvent mentioned in step d).

With the term "about" is meant a deviation of 10 % or less from the given value.

Preferentially, in step a) as reagent *N*-chloroacetyl-2,6-xylidine is used as the latter reagent is cheap and commercially available. However, *N*-bromoacetyl-2,6-xylidine may also be used, as well as mixtures of them in any given ratio.

Preferentially, in step a) the molar ratio is about 3/1. Using less excess of piperazine gives a steep rise in the undesirable adduct. Using more does not essentially decrease the amount of adduct and also makes the process step a) unreasonable in terms of costs and environmental burden. With molar ratio is meant the molar amount of piperazine versus the molar amount of *N*-haloacetyl-2,6-xylidine

Preferentially, in step a) the aqueous solvent is water, although other solvents that are totally or at least to a large extent miscible with water at the given reaction condition may also be used, such as alcohols, in particular methanol, ethanol, propanol, isopropanol, butanol and sec-butanol; THF, aceton and ethylacetate. Also, mixtures of different solvents may be used, for example water/alcohol, in particular water/isopropanol, in different ratios. Obviously, the solvent should be reaction-inert towards the reagents, in particular towards HCl.

Preferentially, step a) is performed by first adding an amount of HCl to a reaction mixture containing the aqueous solvent and piperazine and subsequently adding the *N*-haloacetyl-2,6-xylidine to the reaction mixture. The addition of HCl to the reaction mixture is an exothermic reaction. The reaction is further performed preferentially at an elevated temperature (i.e. above room temperature and below boiling temperature of the reaction mixture). Preferentially, the reaction temperature in step a) is about 60°C to about 90°C, more preferentially about 80°C. By performing the reaction in step a) a solid is produced, which corresponds to the adduct (Formula IV). The reaction time may be chosen to be between 1-24 hours. The desirable end product according to Formula (III) is completely soluble in the reaction mixture.

In step b) the solid obtained in step a) is separated from the reaction mixture. Separation may be performed by any method known to the skilled person. Preferentially, the reaction mixture containing the solid is filtered, preferentially at an elevated temperature, more preferentially at about 60°C. By this step, the adduct is removed nearly completely while the desired end product is kept into solution.

In step c) the acidic filtrate is neutralized up to a pH > about 8. Preferentially, the acidic filtrate is neutralized to a pH equal to about 10. As neutralizing agent, any agent may be used suitable for this purpose, such as, for example a base such as sodium hydroxide, potassium hydroxide and the like.

In step d) the solvent used for the extraction is preferentially toluene. However, other solvents that are not or only to a small extent miscible with the aqueous solvent mentioned in step a) under the given reaction conditions may also be used, such as benzene, THF, methyl-t-butyl ether and methyl-ethyl ketone, as well as mixtures of them in any given ratio. Obviously, the extraction solvent should be reaction-inert. The extraction is preferably performed at elevated temperature, in particular at a temperature between room temperature and the boiling temperature of the extraction solvent used. When toluene is used, the temperature is preferentially between about 60°C and about 80°C, more preferentially at about 70°C.

In step e) the end product is crystallized from the reaction mixture by common methods known to the skilled person. In particular, the extraction solvent may be distilled off to about 2/3 of its volume after which the temperature of the reaction mixture may be lowered, for example down to 0°C. Also, it may be appropriate to seed the reaction mixture to start the crystallization and to obtain large crystals.

Finally, in step f) the solid end product obtained in step e) can be separated from the extraction solvent by commonly known separation methods, such as filtration.

In particular, the invention relates to a process for the production of *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide obtained from the reaction of piperazine with *N*-chloroacetyl-2,6-xylidine, which comprises the subsequent steps a) through f):

a) reacting piperazine with *N*-chloroacetyl-2,6-xylidine at about 80°C in a ratio of about 3/1 in water to which has been added 3 equivalents of HCl ;

b) filtering the reaction mixture at about 60°C ;

c) neutralizing the filtrate up to a pH equal to about 10 ;
d) extracting the filtrate with toluene at 70°C;
e) crystallizing the *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide from toluene and
f) filtering the solid from the filtrate.

The invention will now be illustrated by some examples and comparative experiments without being limited thereto.

Experimental

All materials were purchased from commercial suppliers and used without further purification. All reactions were conducted under an atmosphere of nitrogen. In the lab, only glass vessels are used; in the pilot plant, both steel or glass-lined vessels are used. For each reaction, a sample of the reaction mixture was collected and analysed by means of HPLC.

Example I. Preparation of *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl -acetamide.

In a 250ml, 4-necked flask equipped with a stirrer, piperazine (12.9g, 0.15mol, 3eq.) was suspended in water (15ml, 0.1L/mol piperazine). The mixture was stirred vigorously and HCl$_{sp}$ (12.4ml, 0.15mol, 3eq.) was added cautiously (!exothermic!). The temperature rose to 45°C and the mixture became homogeneous. After cooling to 20-25°C, *N*-haloacetyl-2,6-xylidine (9.9g, 0.05mol, 1eq.) was added, the mixture was heated to 80°C and stirred for 2h. The reaction mixture was then cooled to 60°C and filtered at that temperature over dicalite, in order to remove the precipitate of adduct. The filtrate was treated at 60°C with NaOH 50% in water (8.5ml, 0.16mol, 3.2eq., pH>10) and toluene (120ml, 2.4L/mol) was added. The mixture was then heated to 70°C, stirred 15 min. and the layers separated at that temperature. After discarding the water layer, about 2/3rd of the organic phase was distilled off and the mixture slowly cooled down to 22°C over 3h. Seeding was performed at 60°C. The mixture was further cooled to 0-5°C and stirred at that temperature during 1h. The precipitate was filtered off, washed with toluene (10ml, 0.2L/mol) and dried during 16h at 40°C under vacuum. The end product was obtained as a white precipitate: m.p. 118°C
Yield: 8.6g (70%, 68% active yield). HPLC and base titration give satisfactory results (>97.5% purity).

^{1}H NMR ($CDCl_3$, 360MHz) δ: 1.62 (bs, 1H, NH), 2.22 (s, 6H), 2.63 (m, 4H), 2.93 (m, 4H), 3.15 (s, 2H), 7.02-7.13 (m, 3H), 8.71 (bs, 1H, CONH)

Anal. Calcd. for $C_{14}H_{21}N_30$: C, 67.98; H, 8.56; N, 16.99. Found: C, 68.21; H, 8.38; N, 17.22.

Example II-XI: Effect of different reaction conditions for step a)

Step a) in the preparation according to Example I was repeated for several reaction conditions. The results are summarized in Table 1.

Table 1 : Effect of different reaction conditions for step a).

Example	A	B	C	D	E
II	1/1	0	^{i}PrOH (1L/mol)	21h	62%
III	2/1	0	^{i}PrOH (1L/mol)	2h	28%
IV	3/1	0	^{i}PrOH (1L/mol)	2h	28%
V	2/1	2	^{i}PrOH (0.66L/mol)/H_2O (0.09L/mol)	4h	17%
VI	2/1	2.25	^{i}PrOH (0.66L/mol)/H_2O (0.09L/mol)	4h	17%
VII	2/1	2.5	^{i}PrOH (0.66L/mol)/H_2O (0.09L/mol)	3h	17%
VIII	3/1	3	^{i}PrOH (1L/mol)/H_2O (0.135L/mol)	3h	7%
IX	3/1	3	^{i}PrOH (1L/mol)/H_2O (0.135L/mol)	3h	7%
X	2/1	2	H_2O (0.75L/mol)	21h	7%
I	3/1	3	H_2O (0.4L/mol)	2h	3%

A : Molar ratio in step a)

B : Amount of HCl (equivalent)

C : Solvent used for the reaction in step a)

D : Reaction time (hours)

E : Amount of adduct in the reaction mixture (LC area, %)

Example II-XI: Effect of different extraction and crystallisation media for respectively step d) and e)

Steps d) and e) in the preparation according to Example I were repeated for several reaction media. The results of the extractions and crystallisations (not performed consecutively) are summarized in Table 2. From this Table 2, it can be seen that although ethylacetate is suitable for extraction purposes, only toluene is suitable for extraction and crystallisation purposes, therefor obviating the need to change from extraction medium to a different crystallisation medium.

Table 2. : Effect of different extraction and crystallisation media for respectively step d) and e).

Solvent	Extraction	Crystallisation
Methanol	--	--
Ethanol	--	--
Isopropanol	o	--
N-butanol	o	o
sec-butanol	o	--
Ethylacetate	++ (at r.t.)	o
Toluene	++ (at 70°C)	++

Qualifications : ++ :very good ; + : good ; o : moderate ; -- : not suitable

CLAIMS

1. Process for the production of *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide, obtained from the reaction of piperazine with *N*-haloacetyl-2,6-xylidine, characterized in that the process comprises the subsequent steps a) through f) :
a) reacting piperazine with *N*-haloacetyl-2,6-xylidine in a molar ratio between about 1/1 and about 6/1 in an aqueous solvent in which has been dissolved an about equimolar amount of HCl ;
b) separating the solid formed in step a) from the reaction mixture ;
c) neutralizing the filtrate ;
d) extracting the filtrate with a solvent which is not or only to a small extent miscible with the aqueous solvent mentioned in step a) ;
e) crystallizing the *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide from the solvent mentioned in step d) and
f) separating the solid obtained in step e) from the solvent mentioned in step d).

2. Process according to claim 1 in which *N*-haloacetyl-2,6-xylidine is *N*-chloroacetyl-2,6-xylidine.

3. Process according to any one of claims 1 to 2, characterized in that the molar ratio in step a) is about 3/1 and the equimolar amount of HCl is about 3.

4. Process according to any one of claims 1 to 3, characterized in that solvent for extraction (step d) and crystallization (step e) is toluene.

5. Process according to any one of claims 1 to 4, characterized in that the separation method in step b) and step f) is filtration.

6. Process for the production of *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide, obtained from the reaction of piperazine with *N*-chloroacetyl-2,6-xylidine, characterized in that the process comprises the subsequent steps a) through f) :
a) reacting piperazine with *N*-chloroacetyl-2,6-xylidine at about 80°C in water in a molar ratio of about 3/1, the reaction mixture also containing 3 equivalents of HCl.;

b) filtering the reaction mixture at about 60°C ;

c) neutralizing the filtrate up to a pH equal to about 10 ;

d) extracting the filtrate with toluene at about 70°C;

e) crystallizing the *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide from toluene and

f) filtering the solid *N*-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide.

7. Process as described and elucidated on the basis of the examples.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/50241

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D295/15

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 40664 A (DADE CHEMISTRY SYSTEMS INC) 19 December 1996 (1996-12-19) cited in the application the whole document	1-7
A	US 3 953 448 A (HENSON DAVID W ET AL) 27 April 1976 (1976-04-27) Example 1, part A, B and C	1-7

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
7 November 2003	20/11/2003

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	O'Sullivan, P

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 03/50241

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9640664	A	19-12-1996	AU	6167696 A	30-12-1996
			EP	0775128 A1	28-05-1997
			JP	10504324 T	28-04-1998
			WO	9640664 A2	19-12-1996
US 3953448	A	27-04-1976	DE	2610501 A1	15-09-1977
			CA	1034952 A1	18-07-1978
			GB	1434580 A	05-05-1976